During the corresponding time, Sage Therapeutics Inc recorded a revenue increase by 265.84 % year on year, sequentially revenue grew by 125.13 %. While revenue at the Sage Therapeutics Inc 's corporate clients
Sage Therapeutics, Inc. has recently reported findings from two pivotal clinical studies evaluating newer treatments for neurological conditions, particularly Alzheimer s disease and essential tremor. This article interprets the topline results from the LIGHTWAVE study for dalzanemdor (SAGE-718) regarding mild cognitive impairment and mild dementia in Alzheimer s patients, and the KINETIC 2 study for SAGE-324 (BIIB124) aimed at treating essential tremor. An assessment of these results in conjunction with the company s ongoing developments and financial performance provides insight into the current landscape and future implications for Sage Therapeutics. Sage Therapeutics has become a key player in biopha...
Sage Therapeutics: Advancing Brain Health Through Innovative Therapies and Strong Market Performance Sage Therapeutics, Inc. is at the forefront of transforming brain health through pioneering biopharmaceuticals targeting serious mood disorders, particularly postpartum depression (PPD). This article examines their recent achievements, focusing on the promising commercial performance of ZURZUVAE, a novel treatment, as well as the company s strategic positioning within the biopharmaceutical landscape highlighted in their financial results for Q1 and Q2 of 2024. By analyzing Sage Therapeutics ongoing projects, market presence, and future initiatives, this paper aims to underline the company s commitment to...
In a collaborative effort, Sage Therapeutics, Inc. and Biogen Inc. have recently disclosed the topline findings from the Phase 2 KINETIC 2 study evaluating the potential effectiveness of SAGE-324 (BIIB124) as a treatment for essential tremor (ET). This article aims to outline the key facts derived from this study and assess the impact these results may have on both pharmaceutical companies.Summary of the Study:The Phase 2 KINETIC 2 study was designed to determine the efficacy of SAGE-324 by assessing its impact on the Essential Tremor Rating Assessment Scale (TETRAS) Perform. Regrettably, the study did not demonstrate a statistically significant dose-response relationship in the change from baseline to Day 9...
Sage Therapeutics to Participate in Upcoming Investor Conferences in MayCambridge, Mass. - Sage Therapeutics, a leading biopharmaceutical company focused on improving brain health, has confirmed its participation in two investor conferences in May. The conferences will provide an opportunity for the company to showcase its advancements in the field and engage with potential investors.The first conference, the 2024 RBCCM Global Healthcare Conference, will take place in New York, NY on May 14th. Sage Therapeutics will be hosting a fireside chat at 11:30 a.m. ET, where representatives will discuss the latest developments and address any queries from the audience. This conference will be attended by a wide range...
Sage Therapeutics Surges Ahead with Successful Launch of ZURZUVAE in First Quarter 2024CAMBRIDGE, Mass. - Sage Therapeutics, a biopharmaceutical company dedicated to revolutionizing brain health, has announced its impressive first-quarter financial results and provided updates on its pipeline and business progress. The company s latest launch, ZURZUVAE, has been met with resounding success, particularly amongst healthcare professionals, particularly OBGYNs, igniting an optimistic start for Sage Therapeutics.During the first full quarter of ZURZUVAE s release, Sage Therapeutics witnessed a surge in demand, solidifying its promising market potential. OBGYNs in particular have demonstrated a heightened interest...
Sources:
Sage Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sage Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sage Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %